Nebivolol prevents myocardial fibrosis and diastolic dysfunction in salt-loaded spontaneously hypertensive rats |
| |
Authors: | Dinko Susic Hassan Fares Edward D. Frohlich |
| |
Affiliation: | 1. Department of Urology, Faculty of Medicine, University of Çukurova, Adana, Turkey;2. Department of Pathology, Faculty of Medicine, University of Çukurova, Adana, Turkey;3. Department of Biochemistry, Faculty of Medicine, University of Çukurova, Adana, Turkey;1. Hakkari State Hospital, Internal Medicine Unit, Turkey;2. Hakkari State Hospital, Nephrology Unit, Turkey;1. Translational Science & Molecular Medicine, Michigan State University College of Human Medicine, Hauenstein Neuroscience Center, Grand Rapids, MI, USA;2. Neuropsychology & Clinical Research, Department of Neurology & Rehabilitation, University of Illinois College of Medicine at Chicago, Chicago, IL, USA;1. Hypertension Unit, Hospital 12 de Octubre, and Department of Preventive Medicine and Public Health, Universidad Autónoma, Madrid, Spain;2. Department of Nephrology and Hypertension, University Erlangen Nürnberg, Erlangen, Germany |
| |
Abstract: | BackgroundWe have demonstrated previously that a high-salt diet (HS) produces myocardial fibrosis, left ventricular (LV) dysfunction, and renal insufficiency in adult spontaneously hypertensive rats (SHR), and that blockade of the renin-angiotensin system prevented those adverse effects of HS.Methods and ResultsEight-week-old male SHR were divided into four groups: controls received regular rat chow (0.6 NaCl); the other three were given HS. The second group was given placebo; the third, nebivolol (2 × 10 mg/kg/day) orally; and, the fourth, the same dose of nebivolol by osmotic minipump. Rats received respective treatments for 8 weeks. The data demonstrated that the HS induced increased cardiac mass (2.85 ± 0.05 vs. 5.36 ± 0.22 mg/g; P < .05 in control and HS groups, respectively); LV fibrosis as indicated by higher hydroxyproline concentration; further increase in arterial pressure (161 ± 7 vs. 184 ± 8 mm Hg; P < .05); myocardial ischemia; and LV diastolic dysfunction. Nebivolol ameliorated the adverse cardiac effects of HS, demonstrated by decreased LV mass and fibrosis and improved coronary hemodynamics and LV function.ConclusionsThe effects of nebivolol were independent of arterial pressure. The results of this study provide important laboratory data that support a rationale for nebivolol in the treatment of patients with hypertension having diastolic dysfunction with preserved ejection fraction. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|